Tandem Diabetes launches clinical trial for its automatic insulin delivery suspension

Touchscreen insulin pump maker Tandem Diabetes announced a new clinical trial for an insulin pump with a  predictive low glucose suspend (PLGS) algorithm. Another step on the road to an artificial pancreas, PLGS allows Tandem to automatically suspend insulin delivery when it predicts low glucose and resume it when glucose starts to rise again.
Source: mobihealthnews - Category: Information Technology Source Type: news